Biolinq Shine
Biolinq
Not a T1D device. But it is the first real break from the filament.
The first glucose sensor with no needle and no filament — an array of tiny microsensors that sits in the top layers of the skin, up to 20x shallower than a conventional CGM, with a colour-coded LED on the patch itself so you can read your status without a phone. It won FDA de novo classification in September 2025 as a prescription device for adults with type 2 diabetes who do not take insulin, and a US launch is planned for the second half of 2026. It is not indicated for insulin dosing and drives no pump or loop — we cover it because the sensing approach, not the indication, is what matters.
The scorecard
No overall MARD has been published. The five-day dataset presented at ADA 2026 reports an 11.1% MARD in the low range, 40–70 mg/dL (2.2–3.9 mmol/L), and says more than 30% of sensors came in under 10% MARD overall — which implies most did not. That is well short of the 8–9% MARD of the CGMs cleared for insulin dosing, and Shine is not indicated for insulin dosing at all.[3]
Shine reads intradermally — in the top layers of skin, up to 20 times shallower than a conventional CGM filament. That is a genuinely different sensing compartment and the reason the approach is interesting, but Biolinq has published no lag figure, so we do not credit it with a lag advantage it has not demonstrated.[1]
Closed by design. Shine drives no pump, no automated insulin delivery system and no DIY loop, and is not cleared for insulin dosing. It is a standalone patch that displays its own result.[1]
Roughly five-day wear in the ADA 2026 dataset, with 85% sensor survival and a 98% median display rate — far short of the 10–15 days every mainstream CGM now offers, which means more sensor changes and more cost per month.[3]
Presented as an autonomous sensor — the patch shows your status itself, and the pivotal dataset reports a 98% median five-minute display rate with no calibration protocol described. We read that as factory-calibrated, but no calibration details have been published, so we hold back a little.[3]
A colour-coded LED on the patch tells you at a glance whether you are in range, which is a nice idea — but there are no configurable predictive low/high alarms. It cannot wake you for a nighttime low, which by itself rules it out as a T1D sensor.[1]
The whole point: no introducer needle and no subcutaneous filament, just a microsensor array in the upper layers of skin, plus an on-patch readout so you are not tied to a phone. Adverse events were under 1% in the ADA 2026 dataset.[3]
Glucose only today. Biolinq's stated roadmap is lactate first, then ketones and cortisol — a plan, not a product.[4]
Not yet purchasable anywhere. The FDA de novo makes it a US *prescription* device (not over-the-counter), the launch is planned for the second half of 2026, and the indication covers only adults with type 2 diabetes not on insulin — so for someone with T1D it is, for now, effectively unobtainable and uncovered.[4]
Editor’s take
Read the indication before you get excited: no alarms, no loop, no insulin dosing, five-day wear, and an accuracy figure that has only been disclosed for the low range. This is not a sensor for anyone with T1D, and it is not sold yet. But it is the first credible break from the subcutaneous filament that every CGM has used for twenty years, and the on-patch LED quietly asks a good question about whether a phone should be mandatory. If the wear time doubles and the accuracy reaches iCGM standard, this form factor is where continuous glucose sensing should end up — and the lactate/ketone roadmap is the part that would matter most to us.
The full picture
Biolinq Shine is the first glucose sensor to get rid of both the needle and the filament. Every continuous glucose monitor (CGM) on the market today inserts a thin wire — a filament — through the skin and into the fatty tissue underneath, using a needle to get it there. Shine instead places an array of tiny microsensors in the top layers of the skin, up to 20 times shallower than a conventional CGM's needle, and puts a colour-coded LED on the patch itself so you can glance at your arm and see whether you are in range without reaching for a phone.1
We include it because the sensing approach is important. The indication is not one that applies to anyone reading this site: Shine is authorized for adults with type 2 diabetes who do not use insulin, and it is not indicated for insulin dosing.1
Where it stands
The FDA granted Shine a de novo classification in September 2025 (DEN240080) — a de novo is the pathway for a genuinely new type of device, one with no existing predicate to compare against, which is itself a signal of how different this is.12 It is a prescription device, not an over-the-counter one.1
It is not on sale yet. Biolinq has said Shine launches in the second half of 2026.3 As of mid-July 2026 there is no evidence you can buy one, which is why we file it as pipeline rather than available.
What the data actually show
Biolinq presented a five-day accuracy dataset at ADA 2026: 190 sensor wearers across six US sites, ages 22 to 82.4 The device behaved well as hardware — 85% sensor survival over the wear period, a 98% median five-minute display rate, and adverse events under 1%.4
Accuracy is the part to read carefully. Biolinq reported a MARD of 11.1% in the low range, 40–70 mg/dL (2.2–3.9 mmol/L), and said more than 30% of sensors came in under 10% MARD overall.4 No overall MARD figure was disclosed — and "more than 30% of sensors beat 10%" implies most did not. For comparison, the sensors cleared to drive insulin dosing sit at roughly 8–9% MARD overall. Any number you see quoted as Shine's headline MARD should be treated as unverified until Biolinq publishes one.
Why it is not a T1D sensor
Four reasons, any one of which would be enough:
- No alarms. The LED shows you where you are when you look at it. It cannot wake you at 3am for a low.1
- No loop. Shine drives no pump, no automated insulin delivery (AID) system, and no DIY loop.1
- No insulin indication. It is not cleared for insulin dosing.1
- Five-day wear, against the 10–15 days of every mainstream CGM.4
Why it still matters
The subcutaneous filament has been the unquestioned architecture of CGM for two decades, and it is the source of several of the field's stubbornest problems — insertion pain, adhesive real estate, foreign-body response at the sensor tip, and the interstitial delay that keeps every closed loop reacting to the recent past (see the sensing gap). Shine is the first authorized device to break from it.
Two caveats on the enthusiasm. First, sensing intradermally is a plausible route to lower lag, but Biolinq has published no lag data, so we do not score it as a lag win — only as a different and promising compartment. Second, the thing that would make this genuinely important for T1D is the multi-analyte roadmap: Biolinq says lactate first, then ketones and cortisol.3 Continuous ketone sensing is the frontier safety feature this field needs. It is, today, a roadmap and not a product.
References
-
Drug Delivery Business. Biolinq wins FDA de novo nod for autonomous, needle-free CGM — de novo classification for the Shine wearable biosensor; microsensor array with no subcutaneous introducer needle, sitting up to 20 times more shallow than conventional CGM needles; colour-coded LED on the patch readable without a phone; prescription device; initial indication adults with type 2 diabetes not on insulin (23 September 2025). https://www.drugdeliverybusiness.com/biolinq-fda-nod-autonomous-needle-free-cgm/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
U.S. FDA. De novo classification DEN240080 — primary FDA record. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240080 ↩
-
MedTech Dive. 4 diabetes tech execs on the future of multi-analyte glucose sensors — Biolinq's roadmap is lactate first, then ketones and cortisol; Shine launches in the second half of 2026 (22 June 2026). https://www.medtechdive.com/news/4-diabetes-tech-execs-on-the-future-of-multi-analyte-glucose-sensors/823401/ ↩ ↩2
-
Drug Delivery Business. Biolinq data backs autonomous, needle-free CGM — ADA 2026 presentation: 190 sensor wearers, six US sites, ages 22–82, five-day wear; 85% sensor survival; 98% median five-minute display rate; adverse events under 1%; MARD 11.1% in the 40–70 mg/dL (2.2–3.9 mmol/L) range; more than 30% of sensors under 10% MARD overall; no overall MARD disclosed (8 June 2026). https://www.drugdeliverybusiness.com/biolinq-ada-2026-needle-free-cgm/ ↩ ↩2 ↩3 ↩4
Coming soon
ETA · US launch planned for the second half of 2026 — prescription only, type 2 non-insulin indication
- →US commercial launch (prescription; adults with type 2 diabetes not on insulin) · second half of 2026
- →Multi-analyte versions — lactate first, then ketones and cortisol · roadmap; no dates given
Sources
- [1]Biolinq wins FDA de novo nod for autonomous, needle-free CGM · news · 2025-09-23 — FDA de novo classification for the Shine wearable biosensor — a microsensor array with no subcutaneous introducer needle, sitting "up to 20 times more shallow" than conventional CGM needles, with a colour-coded LED on the patch readable without a phone. Initial indication: adults with type 2 diabetes not on insulin.
- [2]Biolinq Shine — FDA de novo classification DEN240080 · regulatory — Primary FDA record for the de novo. The decision was reported on 23 September 2025; we do not restate an exact FDA decision date here.
- [3]Biolinq data backs autonomous, needle-free CGM (ADA 2026) · conference · 2026-06-08 — ADA 2026 presentation: 190 sensor wearers across six US sites, ages 22–82, five-day wear. 85% sensor survival, 98% median five-minute display rate, adverse events under 1%. MARD of 11.1% reported for the 40–70 mg/dL (2.2–3.9 mmol/L) range; more than 30% of sensors under 10% MARD overall. No overall MARD figure was disclosed.
- [4]4 diabetes tech execs on the future of multi-analyte glucose sensors · news · 2026-06-22 — Biolinq's multi-analyte roadmap — lactate first, then ketones and cortisol — and the statement that Shine launches in the second half of 2026.